Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.06 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: aliskiren fumarate, aliskiren, sitokiren +1 | 1.00 |
| trials ClinicalTrials.gov | 135 Parkinson's trials, 4 stopped | 0.94 |
| literature PubMed | 5 Parkinson's papers of 2,925 | 0.76 |
| pathways Reactome | 1 pathway; mostly energy | 0.60 |
No case: the score is under the bar. Receipt 4426
Sealed predictions
- REN in dopamine neurons, braak-0.68 (p 0.046) → +0.05 (p 0.891)receipt 4433
Swarm cases
receipt 4433: REN in dopamine neurons, braak
- power
- full sample -0.29 (p 0.246, n 18), 95% CI -0.67 to +0.21. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.24 (p 0.346, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.48 (p 0.043, n 18). not the mix.
- skeptic
- leave-one-out range -0.44 to -0.20, sign flips 0; without severely affected donors -0.29 (p 0.246, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for REN in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts